Sei Investments Co. Raises Position in Arcellx, Inc. (NASDAQ:ACLX)

Sei Investments Co. boosted its position in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 99.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,688 shares of the company's stock after acquiring an additional 4,827 shares during the period. Sei Investments Co.'s holdings in Arcellx were worth $743,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. KBC Group NV increased its holdings in Arcellx by 37.3% during the 4th quarter. KBC Group NV now owns 1,388 shares of the company's stock valued at $106,000 after purchasing an additional 377 shares during the period. Avanza Fonder AB bought a new stake in shares of Arcellx in the 4th quarter worth approximately $184,000. Kazazian Asset Management LLC purchased a new position in shares of Arcellx during the fourth quarter valued at approximately $204,000. Xponance Inc. raised its holdings in shares of Arcellx by 8.6% during the fourth quarter. Xponance Inc. now owns 3,088 shares of the company's stock valued at $237,000 after acquiring an additional 244 shares in the last quarter. Finally, Cibc World Markets Corp purchased a new stake in Arcellx in the fourth quarter worth $309,000. 96.03% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Christopher Heery sold 10,155 shares of Arcellx stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $63.79, for a total transaction of $647,787.45. Following the completion of the transaction, the insider now directly owns 37,486 shares in the company, valued at approximately $2,391,231.94. This trade represents a 21.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kavita Patel sold 1,500 shares of the business's stock in a transaction that occurred on Tuesday, April 8th. The stock was sold at an average price of $57.50, for a total value of $86,250.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 55,955 shares of company stock worth $3,507,263. 6.24% of the stock is owned by corporate insiders.

Arcellx Price Performance

NASDAQ:ACLX traded up $2.49 during trading hours on Friday, hitting $59.15. The company had a trading volume of 731,572 shares, compared to its average volume of 557,303. Arcellx, Inc. has a 52 week low of $47.88 and a 52 week high of $107.37. The stock has a 50-day moving average price of $65.44 and a 200 day moving average price of $75.90. The company has a market capitalization of $3.25 billion, a PE ratio of -83.31 and a beta of 0.33.

Arcellx (NASDAQ:ACLX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.24). Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. The firm had revenue of $15.27 million for the quarter, compared to the consensus estimate of $27.42 million. Analysts anticipate that Arcellx, Inc. will post -1.58 EPS for the current fiscal year.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).